Biological evaluation of an ornithine-modified 99mTc-labeled RGD peptide as an angiogenesis imaging agent

被引:26
|
作者
Tsiapa, Irene [1 ]
Loudos, George [2 ]
Varvarigou, Alexandra [3 ]
Fragogeorgi, Eirini [2 ,3 ]
Psimadas, Dimitrios [2 ,3 ]
Tsotakos, Theodoros [2 ,3 ]
Xanthopoulos, Stavros [3 ]
Mihailidis, Dimitris [4 ]
Bouziotis, Penelope [3 ]
Nikiforidis, George C. [1 ]
Kagadis, George C. [1 ]
机构
[1] Univ Patras, Dept Med Phys, Sch Med, GR-26504 Rion, Greece
[2] Inst Educ Technol, Dept Med Instruments Technol, GR-12210 Athens, Greece
[3] NCSR Demokritos, Inst Radioisotopes Radiodiagnost Prod, GR-15310 Aghia Paraskevi, Greece
[4] Charleston Radiat Therapy Consultants, Charleston, WV 25304 USA
关键词
RGD; Integrin alpha(v)beta(3); Technetium; Radiolabeling; Chelator; Ornithine; ALPHA-V-BETA-3; INTEGRIN; RENAL UPTAKE; TUMOR; RADIOPHARMACEUTICALS; PHARMACOKINETICS; BOMBESIN; RHENIUM(V); COMPLEXES; CHELATORS; DELIVERY;
D O I
10.1016/j.nucmedbio.2012.10.015
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Introduction: Radiolabeled RGD peptides that specifically target integrin alpha(v)beta(3) have great potential in early tumor detection through noninvasive monitoring of tumor angiogenesis. Based on previous findings of our group on radiopeptides containing positively charged aminoacids, we developed a new cyclic cRGDfK derivative, c(RGDfK)-(Orn)(3)-CGG. This new peptide availing the polar linker (Orn)(3) and the Tc-99m-chelating moiety CGG (Cys-Gly-Gly) is appropriately designed for Tc-99m-labeling, as well as consequent conjugation onto nanoparticles. Methods: A tumor imaging agent, c(RGDfK)-(Orn)(3)-[CGG-Tc-99m], is evaluated with regard to its radiochemical, radiobiological and imaging characteristics. Results: The complex c(RGDfK)-(Orn)(3)-[CGG-Tc-99m] was obtained in high radiochemical yield (>98%) and was stable in vitro and ex vivo. It presented identical to the respective, fully analytically characterized Re-185/187 complex retention time in RP-HPLC. In contrary to other RGD derivatives, we showed that the new radiopeptide exhibits kidney uptake and urine excretion due to the ornithine linker. High tumor uptake (3.87 +/- 0.48% ID/g at 60 min p.i.) was observed and was maintained relatively high even at 24 h p.i. (1.83 +/- 0.05 % ID/g), thus providing well-defined scintigraphic imaging. Accumulation in other organs was negligible. Blocking experiments indicated target specificity for integrin receptors in U87MG glioblastoma cells. Conclusion: Due to its relatively high tumor uptake, renal elimination and negligible abdominal localization, the new Tc-99m-RGD peptide is considered promising in the field of imaging alpha(v)beta(3)-positive tumors. However, the preparation of multifunctional SPECT/MRI contrast agents (RGD-conjugated nanoparticles) for dual modality imaging of integrin expressing tumors should be further investigated. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:262 / 272
页数:11
相关论文
共 50 条
  • [1] Evaluation of ανβ3-Mediated Tumor Expression with a 99mTc-Labeled Ornithine-Modified RGD Derivative During Glioblastoma Growth In Vivo
    Tsiapa, Irene
    Loudos, George
    Fragogeorgi, Eirini A.
    Bouziotis, Penelope
    Psimadas, Dimitrios
    Xanthopoulos, Stavros
    Paravatou-Petsotas, Maria
    Palamaris, Lazaros
    Varvarigou, Alexandra D.
    Karnabatidis, Dimitris
    Kagadis, George C.
    [J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2014, 29 (10) : 444 - 450
  • [2] Evaluation of 99mTc-labeled cyclic RGD peptide dimers with chelating HYNIC: impact of RGD peptide and 99mTc chelate
    Kim, Young-Seung
    Zhou, Yang
    Lu, Xin
    Gao, Haijun
    Liu, Shuang
    [J]. NUCLEAR MEDICINE AND BIOLOGY, 2010, 37 (06) : 708 - 708
  • [3] Development and evaluation of 99mTc-labeled LHRH peptide as potential tumor imaging agent
    Camacho, Ximena
    Cabrera, Mirel
    Alfaya, Lucia
    Garcia, Maria Fernanda
    Lecot, Nicole
    Fernandez, Marcelo
    Gambini, Juan
    Cabral, Pablo
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2017, 58
  • [4] Synthesis and radiobiological evaluation of a new 99mTc-labeled small peptide: 99mTc-YGGSLAK as imaging agent
    De, Kakali
    Chandra, Susmita
    Ganguly, Santanu
    Sarkar, Bhart
    Misra, Mridula
    [J]. JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2011, 54 (07): : 374 - 381
  • [5] 99mTc-Galacto-RGD2: A Novel 99mTc-Labeled Cyclic RGD Peptide Dimer Useful for Tumor Imaging
    Ji, Shundong
    Czerwinski, Andrzej
    Zhou, Yang
    Shao, Guoqiang
    Valenzuela, Francisco
    Sowinski, Pawel
    Chauhan, Satendra
    Pennington, Michael
    Liu, Shuang
    [J]. MOLECULAR PHARMACEUTICS, 2013, 10 (09) : 3304 - 3314
  • [6] Evaluation of 99mTc-Labeled Cyclic RGD Dimers: Impact of Cyclic RGD Peptides and 99mTc Chelates on Biological Properties
    Zhou, Yang
    Kim, Young-Seung
    Lu, Xin
    Liu, Shuang
    [J]. BIOCONJUGATE CHEMISTRY, 2012, 23 (03) : 586 - 595
  • [7] Development of a 99mTc-labelled RGD peptide as an angiogenesis imaging agent
    Iveson, Peter
    Morrison, Matthew
    Barnett, Jon
    [J]. NUCLEAR MEDICINE AND BIOLOGY, 2010, 37 (06) : 707 - 707
  • [8] Solid phase synthesis, radiolabeling and biological evaluation of a 99mTc-labeled αVβ3 tripeptide (RGD) conjugated to DOTA as a tumor imaging agent
    Varshney, Raunak
    Hazari, Puja Panwar
    Uppal, Jasleen Kaur
    Pal, Sunil
    Stromberg, Roger
    Allard, Michele
    Mishra, Anil Kumar
    [J]. CANCER BIOLOGY & THERAPY, 2011, 11 (10) : 893 - 901
  • [9] Synthesis and preliminary biological evaluation of a 99mTc-labeled hypericin derivative as a necrosis avid imaging agent
    Fonge, Humphrey
    Jin, Lixin
    Wang, Huaijun
    Bormans, Guy
    Ni, Yicheng
    Verbruggen, Alfons
    [J]. JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2008, 51 (1-2): : 33 - 40
  • [10] Comparison of biological properties of 99mTc-labeled cyclic RGD Peptide trimer and dimer useful as SPECT radiotracers for tumor imaging
    Zhao, Zuo-Quan
    Yang, Yong
    Fang, Wei
    Liu, Shuang
    [J]. NUCLEAR MEDICINE AND BIOLOGY, 2016, 43 (11) : 661 - 669